Literature DB >> 7785984

Evaluation of maduramicin and alborixin in a SCID mouse model of chronic cryptosporidiosis.

J R Mead1, X You, J E Pharr, Y Belenkaya, M J Arrowood, M T Fallon, R F Schinazi.   

Abstract

Two polyether ionophores, maduramicin and alborixin, were evaluated for anticryptosporidial activity in a severe combined immune deficient (SCID) mouse model of cryptosporidiosis. Groups of SCID mice were inoculated with 10(6) oocysts of bovine origin by oral gavage. Maduramicin or alborixin was administered beginning 4 weeks postinfection at 3 mg/kg of body weight per day. Maduramicin treatment resulted in a 96% reduction in fecal parasite load over the 3-week treatment period (P < 0.003). This reduction correlated with decreases in tissue parasite loads observed in histological sections of the small intestine (P < 0.000002) and the colon (P < 0.000006). A significant decrease in oocyst shedding was also observed after a 3-week treatment with alborixin (71% reduction, P < 0.01). Maduramicin was also evaluated in a relapsing model of cryptosporidiosis in which the infection was observed to recur after treatments were discontinued. Some toxicity, as demonstrated by weight loss, was observed with both maduramicin and alborixin. Both drugs exhibited significant anticryptosporidial activities with concomitant moderate toxicity. These polyether ionophores should be valuable as positive controls in compound evaluation studies and as lead compounds for chemical optimization (modification).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7785984      PMCID: PMC162642          DOI: 10.1128/AAC.39.4.854

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Experimental cryptosporidiosis in hamsters.

Authors:  P Rossi; E Pozio; M G Besse; M A Gomez Morales; G La Rosa
Journal:  J Clin Microbiol       Date:  1990-02       Impact factor: 5.948

2.  Eimeria: effect of meticlorpindol and methyl benzoquate on endogenous stages in the chicken.

Authors:  P L Long; B J Millard
Journal:  Exp Parasitol       Date:  1968-12       Impact factor: 2.011

3.  In vitro assays of maduramicin activity against Cryptosporidium parvum.

Authors:  M J Arrowood; L T Xie; M R Hurd
Journal:  J Eukaryot Microbiol       Date:  1994 Sep-Oct       Impact factor: 3.346

4.  Experimental cryptosporidiosis in laboratory mice.

Authors:  D Sherwood; K W Angus; D R Snodgrass; S Tzipori
Journal:  Infect Immun       Date:  1982-11       Impact factor: 3.441

5.  Putative anticryptosporidial agents tested with an immunodeficient mouse model.

Authors:  G J Leitch; Q He
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 6.  Human immunodeficiency virus infection and cryptosporidiosis: protective immune responses.

Authors:  T P Flanigan
Journal:  Am J Trop Med Hyg       Date:  1994       Impact factor: 2.345

7.  Infection dynamics and clinical features of cryptosporidiosis in SCID mice.

Authors:  J R Mead; N Ilksoy; X You; Y Belenkaya; M J Arrowood; M T Fallon; R F Schinazi
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

8.  The therapeutic effect of 16 antimicrobial agents on Cryptosporidium infection in mice.

Authors:  S R Tzipori; I Campbell; K W Angus
Journal:  Aust J Exp Biol Med Sci       Date:  1982-04

9.  Infection dynamics of Cryptosporidium parvum (Apicomplexa: Cryptosporiidae) in neonatal mice (Mus musculus).

Authors:  J A Ernest; B L Blagburn; D S Lindsay; W L Current
Journal:  J Parasitol       Date:  1986-10       Impact factor: 1.276

10.  Persistent Cryptosporidium infection in congenitally athymic (nude) mice.

Authors:  J Heine; H W Moon; D B Woodmansee
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

View more
  7 in total

1.  Genomics-driven discovery of the biosynthetic gene cluster of maduramicin and its overproduction in Actinomadura sp. J1-007.

Authors:  Ran Liu; Fang Fang; Ziheng An; Renqiong Huang; Yong Wang; Xiao Sun; Shuai Fu; Aisi Fu; Zixin Deng; Tiangang Liu
Journal:  J Ind Microbiol Biotechnol       Date:  2019-12-18       Impact factor: 3.346

2.  Dicyclic and tricyclic diaminopyrimidine derivatives as potent inhibitors of Cryptosporidium parvum dihydrofolate reductase: structure-activity and structure-selectivity correlations.

Authors:  R G Nelson; A Rosowsky
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

3.  The gamma interferon gene knockout mouse: a highly sensitive model for evaluation of therapeutic agents against Cryptosporidium parvum.

Authors:  J K Griffiths; C Theodos; M Paris; S Tzipori
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

4.  Polyether ionophores: broad-spectrum and promising biologically active molecules for the control of drug-resistant bacteria and parasites.

Authors:  Dion A Kevin Ii; Damaris Af Meujo; Mark T Hamann
Journal:  Expert Opin Drug Discov       Date:  2009-02       Impact factor: 6.098

5.  Bobel-24 activity against Cryptosporidium parvum in cell culture and in a SCID mouse model.

Authors:  Cristina Rueda; Soledad Fenoy; Fernando Simón; Carmen Del Aguila
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

6.  A cysteine protease inhibitor rescues mice from a lethal Cryptosporidium parvum infection.

Authors:  Momar Ndao; Milli Nath-Chowdhury; Mohammed Sajid; Victoria Marcus; Susan T Mashiyama; Judy Sakanari; Eric Chow; Zachary Mackey; Kirkwood M Land; Matthew P Jacobson; Chakrapani Kalyanaraman; James H McKerrow; Michael J Arrowood; Conor R Caffrey
Journal:  Antimicrob Agents Chemother       Date:  2013-09-23       Impact factor: 5.191

7.  Oleylphosphocholine (OlPC) arrests Cryptosporidium parvum growth in vitro and prevents lethal infection in interferon gamma receptor knock-out mice.

Authors:  Karine Sonzogni-Desautels; Axel E Renteria; Fabio V Camargo; Thomas Z Di Lenardo; Alexandre Mikhail; Michael J Arrowood; Anny Fortin; Momar Ndao
Journal:  Front Microbiol       Date:  2015-09-23       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.